ArticleJournal of translational medicine2025
Comparative analysis of statistical and deep learning-based multi-omics integration for breast cancer subtype classification.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Decoding cancer with artificial intelligence: Transforming research, diagnosis, and therapy with future insights.Translational oncology · 2026Review
- Deep Generative and Graph-Based Representation Learning for Multiomics Survival Stratification in Ovarian Cancer: Secondary Analysis.JMIR bioinformatics and biotechnology · 2026Article
- Decoding the cancer microbiome: multi-omics, AI, and translational opportunities.Genome biology · 2026Review
- Construction of Rheumatoid Arthritis-Associated Interstitial Lung Disease diagnostic model and identification of biomarkers based on a multi-omics integration strategy of machine learning.Clinics (Sao Paulo, Brazil) · 2026Article
- RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets.MedComm · 2026Review
- AI-assisted multimodal data integration for precision oncology.Frontiers in artificial intelligence · 2026Review
- Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring.Biomedicines · 2025Review
- Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers.Clinical and experimental medicine · 2025Review
- Special Issue "Advances in Targeted Cancer Therapy and Mechanisms of Resistance-2nd Edition".International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBreast cancer (BC) is a critical cause of cancer-related death globally. The heterogeneity of BC subtypes poses challenges in understanding molecular mechanisms, early diagnosis, and disease management. Recent studies suggest that integrating multi-omics layers can significantly enhance BC subtype identification. However, evaluating different multi-omics integration methods for BC subtyping remains ambiguous.
methodsIn this study, we conducted a multi-omics integration analysis on 960 BC patient samples, incorporating three omics layers: Host transcriptomics, epigenomics, and shotgun microbiome. We compared two integration approaches the statistical-based approach (MOFA+) and a deep learning-based approach (MOGCN) for this integration. We evaluated both methods using complementary evaluation criteria. First, we assessed the ability of selected features to discriminate between BC subtypes using both linear and nonlinear classification models. Second, we analyzed the biological relevance of the selected features to key BC pathways, focusing on transcriptomics-driven insights.
resultsOur results showed that MOFA+ outperformed MOGCN in feature selection, achieving the highest F1 score (0.75) in the nonlinear classification model, with MOFA+ also identifying 121 relevant pathways compared to 100 from MOGCN. Notably, one of the key pathways Fc gamma R-mediated phagocytosis and the SNARE pathway was implicated, offering insights into immune responses and tumor progression.
conclusionThese findings suggest that MOFA+ is a more effective unsupervised tool for feature selection in BC subtyping. Our study underscores the potential of multi-omics integration to improve BC subtype prediction and provides critical insights for advancing personalized medicine in BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.